Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

NCT01958060 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 1034020
DRUG: Placebo to BI 1034020

Sponsor

Boehringer Ingelheim